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ORIGINAL ARTICLE
Ultrasound- Versus Fluoroscopy-Guided Strategy 
for Transfemoral Transcatheter Aortic Valve 
Replacement Access
A Systematic Review and Meta-Analysis
Rafail A. Kotronias , MBChB, MSc*; Jonathan J.H. Bray , MBChB, BSc*; Skanda Rajasundaram, BA; Flavien Vincent , MD, PhD; 
Cedric Delhaye, MD; Roberto Scarsini , MD; Federico Marin , MD; Dimitrios Terentes-Printzios, MD, PhD;  
Julian P.J. Halcox, MD, MB, BChir, BA; Mamas A. Mamas , BMBCh, DPhil; Rajesh Kharbanda, MD, PhD; Eric Van Belle , MD, PhD; 
Adrian P. Banning , MBBS, MD
BACKGROUND: Access site vascular and bleeding complications remain problematic for patients undergoing transcatheter 
aortic valve replacement (TAVR). Ultrasound-guided transfemoral access approach has been suggested as a technique to 
reduce access site complications, but there is wide variation in adoption in TAVR. We performed a systematic review and 
meta-analysis to compare access site vascular and bleeding complications according to the Valve Academic Research 
Consortium-2 classification following the use of either ultrasound- or conventional fluoroscopy-guided transfemoral 
TAVR access.
METHODS: Medline, Embase, Web of Science, and The Cochrane Library were searched to November 2020 for studies 
comparing ultrasound- and fluoroscopy-guided access for transfemoral TAVR. A priori defined primary outcomes were 
extracted: (1) major, (2) minor, and (3) major and minor (total) access site vascular complications and (4) life-threatening/
major, (5) minor, and (6) life-threatening, major, and minor (total) access site bleeding complications.
RESULTS: Eight observational studies (n=3875) were included, with a mean participant age of 82.8 years, STS score 5.81, 
and peripheral vascular disease in 23.5%. An ultrasound-guided approach was significantly associated with a reduced risk 
of total (Mantel-Haenszel odds ratio [MH-OR], 0.50 [95% CI, 0.35–0.73]), major (MH-OR, 0.51 [95% CI, 0.35–0.74]), and 
minor (MH-OR, 0.59 [95% CI, 0.38–0.91]) access site vascular complications. Ultrasound guidance was also significantly 
associated with total access site bleeding complications (MH-OR, 0.59 [95% CI, 0.39–0.90]). The association remained 
significant in sensitivity analyses of maximally adjusted minor and total vascular access site complications (MH-OR, 0.51 
[95% CI, 0.29–0.90]; MH-OR, 0.44 [95% CI, 0.20–0.99], respectively).
CONCLUSIONS: In the absence of randomized studies, our data suggests a potential benefit for ultrasound guidance to obtain 
percutaneous femoral access in TAVR.
REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42020218259.
GRAPHIC ABSTRACT: An online graphic abstract is available for this article.
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Despite procedural advances in transcatheter aortic valve replacement (TAVR), vascular and bleeding complications remain problematic.1 According to a 
recent meta-analysis of studies using contemporary tis-
sue heart valve systems, access site vascular and bleed-
ing complications are encountered in up to 10% and 
14% of TAVR cases, respectively.2 Moreover, the occur-
rence of access site complications are known to be asso-
ciated with higher rates of morbidity and mortality3 and 
increased costs associated with prolonged length of stay.4
Transfemoral TAVR access is the preferred access site 
for >90% of TAVR procedures and has historically been 
obtained using anatomic landmarks and fluoroscopic 
guidance via opacification of the common femoral artery 
from the contralateral (secondary) access—fluoroscopic 
contralateral access (FCA) technique.5 Ultrasound-
guided transfemoral access has been proposed as an 
alternative strategy to reduce access site complications,6 
as it offers real-time, cross-sectional visualization of the 
puncture site anatomy reducing accidental vascular injury 
and enhancing the efficacy of vascular closure devices.7 
Ultrasound has been recommended by some Interven-
tional Society Guidelines,8 but there is currently, no con-
clusive data confirming whether an ultrasound-guided 
transfemoral access strategy confers superior outcomes 
to an FCA strategy during TAVR. Therefore, we set out to 
perform a systematic review and meta-analysis to assess 
the evidence for access site vascular and bleeding com-
plication rates comparing the use of either modality to 
guide transfemoral access in TAVR.
METHODS
This review is written in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
statement9 and is registered with PROSPERO. Ethical approval 
was not sought because of the systematic review and meta-
analysis nature of this study.
Search Strategy
The search strategy used for this study is presented in the 
methods in the Data Supplement.
Study Selection
We selected studies that compared ultrasound- and fluoros-
copy-guided transfemoral access, with 2 groups of participants 
pertaining to each intervention. We excluded TAVR by any other 
route, any studies referring to nonaccess site related complica-
tions, pediatric operations, and any study which could not be 
quantitatively assessed through meta-analysis. No limits were 
set on language.
Outcomes of Interest and Comparisons
We defined the following primary end points a priori: (1) major, 
(2) minor and (3) total (major and minor) access site vascu-
lar complications, (4) life-threatening and major, (5) minor, and 
(6) total (life-threatening, major and minor) access site bleed-
ing complications. We defined a priori the requirement for red 
blood cells transfusion as a secondary end point. Where pos-
sible, adjusted end point data were collected. Where relevant 
end point data was missing, where possible, it was sought from 
corresponding authors via email or by search of data reposi-
tories. Complications were included if recorded in accordance 
with the Valve Academic Research Consortium-2 standardizing 
end point reporting system.10
Data Extraction and Synthesis
Data were independently transferred from full manuscripts 
into preformatted tables by 2 reviewers (J.J.H. Bray and S. 
Rajasundaram). The extraction process is described in more 
detail in methods in the Data Supplement. The authors declare 
that all supporting data are available within the article and in the 
Data Supplement.
Quality and Risk of Bias Assessment
The Cochrane Risk of Bias in Nonrandomised Studies of 
Interventions tool was used to assess risk of bias.11 Degree 
of confidence in the influence of ultrasound- or fluoroscopy-
guidance on selected outcomes was assessed using the 
Grading of Recommendations Assessment, Development 
and Evaluation tool.12
Statistical Analysis
Data are presented as mean or median, unless stated other-
wise. Study end points were analyzed using Mantel-Haenszel 
random effects meta-analyses (Review Manager [RevMan] 
5.3, Copenhagen: The Nordic Cochrane centre 2014). I2 
statistics were calculated to assess for evidence of signifi-
cant heterogeneity. An alpha value of <0.05 was considered 
Nonstandard Abbreviations and Acronyms
FCA fluoroscopic contralateral access
TAVR transcatheter aortic valve replacement
MH-OR  Mantel-Haenszel odds ratio
WHAT IS KNOWN
• Ultrasound-guided transfemoral access has been 
suggested to reduce access site complications in 
transcatheter aortic valve replacement.
WHAT THE STUDY ADDS
• An ultrasound-guided approach for transcatheter 
aortic valve replacement access is associated with 
a 50% reduced risk of major and minor access site 
vascular complications and a ≈40% reduced risk of 
life-threatening, major, and minor access site bleed-
ing complications.
• In the absence of randomized data, we recommend 
that ultrasound guidance is considered to obtain 
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statistically significant. The robustness of the data analyzed, 
analysis methods, and heterogeneity was explored with sen-
sitivity analyses. Heterogeneity was explored in meta-analy-
ses of outcomes with evidence for substantial heterogeneity 
(I2≥50%) using the sequential study removal algorithm and a 
desired I2 threshold of <50%.13
RESULTS
Our search identified 1844 articles. Eight observa-
tional studies were considered eligible (Figure 1), col-
lectively consisting of 3875 participants (median, 458; 
range, 154–1171).6,7,14–21 Seven of the included studies 
(n=3488) were published between 2019 and 2020,7,15–
19,21 and at least 7 (n=3043) included contemporary 
generation valve types.6,7,16,17,19,21 Data was available from 
full texts in 6 studies,6,7,14,17,19,21 from a research letter in 
one study18 and from an abstract in one study.16 As the 
full text for the study by Bouteau et al14,15 was only avail-
able as a thesis in French, it was translated into English 
before data extraction. Since the study by Potluri et al19 
did not report sufficient data to ascertain access site 
related bleeding complications, bleeding outcomes were 
taken from Basra et al20; a study from the same center 
and authors with an overlapping study time periods that 
provided sufficient data to adjudicate bleeding events as 
access site related.
The studies were from international centers and 
populations (2 United Kingdom, 2 France, 1 Australia, 1 
Canada, 1 Finland, and 1 United States). Characteristics 
of included studies were overall generalizable and com-
parable (Table). Participants from included studies had 
a mean age of 82.8 years and 49.8% were female. In 
addition to the characteristics shown in Table and Table 
I in the Data Supplement, participants had a Society of 
Thoracic Surgeons score of 5.81, 30.4% had diabetes, 
23.5% had peripheral vascular disease, and 48.6% had 
coronary artery disease. Four studies indicated that TAVR 
was performed by experienced operators6,14,19,21 while all 
other studies did not specify operator experience.
Risk of Bias and Quality Assessment
Included studies used record linkage or active follow-
up for outcome ascertainment.6,7,14,17,21 In articles that 
referred to missing data, it was reported as being <5% 
and controlled for adequately.6,7,14 Four studies adjusted 
end points of interest for multiple confounders, either 
through multivariate analysis17,21 or through propensity 
matching.7,18 Using the Risk of Bias in Nonrandomised 
Studies of Interventions tool, we identified 4 studies at 
moderate risk of bias7,17,18,21 and 4 at serious risk of bias 
(Table II in the Data Supplement).6,14,16,19 The driver of 
serious and moderate risk of bias in all cases was adjust-
ment for confounders. One study only adjusted for Soci-
ety of Thoracic Surgeons score.14 Moderate risk of bias 
was also driven by inadequate blinding relating to data 
handling in most cases.6,7,17,21 The appraisal of our evi-
dence according to the GRADE tool was deemed as of 
very low certainty owing to the observational nature of 
the included studies (Table III in the Data Supplement).
Access Site Vascular Complications
Crude event rates are shown in Table IV in the Data 
Supplement. Crude major and minor (total) access site 
vascular complications were ascertained in 7 studies and 
occurred in 12.2% (451/3710) of patients.6,7,14,17–19,21 
Crude major access site vascular complications were 
reported in 8 studies and occurred in 5.5% (211/3864) 
of patients.6,7,14,16–19,21 Minor access site vascular compli-
cations were ascertained in 7 studies and occurred in 
6.6% (244/3710) of patients.6,7,14,17–19,21
In aggregate level meta-analyses of up to 8 stud-
ies (n=3864),6,7,14,16–19,21 use of ultrasound guidance for 
transfemoral access in TAVR procedures was associ-
ated with significant reductions in the risk of total, major, 
and minor access site vascular complications (Figure 2). 
The strongest associations were observed in reduction 
of total and major access site vascular complications 
(Mantel-Haenszel odds ratio [MH-OR], 0.50 [95% CI, 
0.35–0.73], I2=65%, n=7 and MH-OR, 0.51 [95% CI, 
0.35–0.74], I2=30%, n=8, respectively). Similarly, minor 
access site vascular complications reductions were 
associated with an ultrasound-guided approach (MH-
OR, 0.59 [95% CI, 0.38–0.91], I2=56%, n=7).
Figure 1. Flow diagram based on PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses).9
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Access Site Bleeding Complications
Crude event rates are shown in Table IV in the Data Sup-
plement. Crude life-threatening, major and minor (total) 
access site bleeding complications were ascertained in 
5 studies and occurred in 11.0% (274/2490) of patie
nts.6,7,17,20,21 Crude life-threatening and major access site 
bleeding complications were reported in 6 studies and 
occurred in 5.9% (162/2760) of patients.6,7,17,18,20,21 Minor 
access site bleeding complications were ascertained in 
5 studies and occurred in 5.1% (126/2490) of patients, 
respectively.6,7,17,20,21
In aggregate level meta-analyses of up to 6 studies 
with 2760 participants,6,7,17,18,20,21 the adoption of ultra-
sound guidance for TAVR transfemoral access was 
associated with a significant reduction in the risk of total 
access site bleeding complications (MH-OR, 0.59 [95% 
CI, 0.39–0.90], I2=52%, n=5). Ultrasound guidance 
was also associated with reductions in the risk of life-
threatening and major, and minor access site bleeding 
complications but these did not reach statistical signifi-
cance (MH-OR, 0.52 [95% CI, 0.26–1.04], I2=69%, n=6 
and MH-OR, 0.67 [95% CI, 0.34–1.31], I2=59%, n=5, 
respectively; Figure 3).
Transfusion of Red Blood Cells
Only 3 studies reported data on requirement for transfu-
sion of at least 1 unit of red blood cells (1748 participants), 
which reached a crude rate of 8.3% (146/1748).6,7,21 
There was no significant association of ultrasound- or 
fluoroscopy-guided transfemoral approach with blood 
transfusion requirement.
Sensitivity Analysis
We conducted sensitivity analysis of the data analyzed, 
bias severity, analysis methodology implemented, and 
heterogeneity observed, as summarized in Table V in the 
Data Supplement. Maximally adjusted minor and total 
access site vascular complications remained significant 
with a comparable effect estimate (MH-OR, 0.51 [95% 
CI, 0.29–0.90], I2=21%, n=4 and MH-OR, 0.44 [95% 
CI, 0.20–0.99], I2=75%, n=4, respectively; Table V in the 
Data Supplement and Figure 4).7,17,18,21 Whereas, maxi-
mally adjusted major access site vascular complications 
became marginally nonsignificant maintaining a compa-
rable effect direction and size (MH-OR, 0.49 [95% CI, 
0.24–1.02], I2=75%, n=4; 23, 26–28). The direction of 
the effect estimates for maximally adjusted access site 
bleeding complications remained the same but was only 
based on 2 studies per end point (Tables V and VI and 
Figure I in the Data Supplement).7,18,21
The reduction of heterogeneity to below 50% led to 
an increase in the magnitude of the ultrasound-guided 
strategy effect estimate for life-threatening/major 
and total access site bleeding complications (Table V 
in the Data Supplement). Consequently, in this homo-
geneous study subgroup ultrasound-guided strategy 
was significantly associated with reductions in life-
threatening and major bleeding complications. Minor 
bleeding complications were associated with either 
access guidance strategy. The magnitude of the effect 
estimate for total vascular complication was greater, 
but the reduction in minor vascular complications 
became not significant (Table V in the Data Supple-
ment). Finally, the direction of the effect estimate did 
not change upon exclusion of studies at severe risk of 
bias (Table V in the Data Supplement).
DISCUSSION
The main finding of this meta-analysis of 8 observational 
studies is that ultrasound-guided access for transfemo-
ral TAVR is associated with a 50% and ≈40% reduc-
tion in the risk of access site vascular and bleeding 
complications, respectively. Although the study synthe-
sizes data from low-moderate quality studies, sensitivity 
analysis including maximally adjusted results shows that 
Table. Study Design Features and Key Characteristics
Study (first author, 
year)
Participants 
included (n) Sheath sizes (Fr) Valve type
Ultrasound 
technique
Temporal relation of 
compared cohorts*
Kotronias, 202017 529 14–20 SAPIEN 3, Lotus, Corevalve, AcurateNeo Long axis Sequential
Potluri, 202019 612 14–20 SAPIEN 3, Evolut-R Short axis Sequential with overlap
Vincent, 20207 190 14–19 SAPIEN XT, SAPIEN 3, Corevalve, Evolut-R Short+long axis Sequential
Witberg, 202021 1171 14–20 SAPIEN XT, SAPIEN 3, Evolut-R, Lotus, 
ACCURATE neo, Portico
Short+long axis Parallel
Bouteau, 201914 573 … Corevalve (59.6%) … Sequential
Moriyama, 201918 246 … … Long axis† …
Khan, 201916 154 14–16 SAPIEN 3 … …




*Sequential indicates fluoroscopy cohort preceded ultrasound cohort. Parallel design is reported to mitigate against temporal bias.
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ultrasound guidance is associated with a significant 56% 
reduction in access site vascular complications. In the 
absence of randomized studies, the current study rep-
resents an important synthesis of available evidence and 
should inform clinical practice.
Femoral Artery Access Techniques and 
Modifications
Historically, transfemoral TAVR access has been obtained 
using anatomic landmarks under fluoroscopic guidance—
the FCA technique.5 Based on the substantial literature 
supporting the adoption of a transradial approach for 
percutaneous coronary intervention,22 the FCA technique 
has been modified to establish secondary access via a 
radial route.23 A meta-analysis of 6 observational studies 
showed that this modification was associated with lower 
risk of major vascular and bleeding complications.24 This 
is relevant as up to a quarter of vascular and bleeding 
access complications are attributed to the secondary 
vascular access site.25
Role of Ultrasound Guidance in Percutaneous 
Large-Bore Arterial Access
Ultrasound guidance for percutaneous arterial access 
offers a real-time, high spatial resolution, and radiation-
free technique to study the anatomy of the vascular tree. 
Ultrasound guidance for procedures requiring percuta-
neous large-bore arterial access (eg, TAVR, ventricular 
assist devices, endovascular aneurysm repair) is of con-
siderable clinical relevance as it prevents inadvertent 
Figure 2. Meta-analyses evaluating risk of access site vascular complications of an ultrasound-guided vs fluoroscopy-guided 
transcatheter aortic valve replacement access strategy. 
Major and minor access site vascular complications (A), major access site vascular complications (B), and minor access site vascular 
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arterial injury and enhances the efficacy of percutaneous 
vascular closure, modifying the risk of access site vascu-
lar and bleeding complications.7
Impact of Ultrasound Guidance on Access Site 
Complications
The impact of ultrasound-guided femoral artery access on 
access site complications has been investigated extensively 
for coronary angiography/percutaneous coronary inter-
vention26 but less so for large-bore arterial access proce-
dures.27 Despite the conflicting evidence regarding the role 
of ultrasound guidance for coronary angiography, a recent 
meta-analysis of randomized controlled trials showed that 
ultrasound guidance was associated with a reduction in 
bleeding events.28 The results of our meta-analysis are 
consistent with this finding. The adoption of ultrasound by 
centers in our meta-analysis was associated with almost 
halving of vascular and bleeding complications.
This association remained significant for both major 
and minor access site vascular complications. However, 
the association of ultrasound guidance with bleeding com-
plications reduction was no longer statistically significant 
when total access site bleeding complications were sepa-
rated into life-threatening and major, and minor access site 
complications. This may partly be attributed to between 
study heterogeneity and the insufficient power of the 
meta-analysis due to the low number of bleeding events. 
The lower number of events when compared with vascular 
complications is expected since access site bleeding is 
usually due to an access site vascular injury7 and is within 
rates described in contemporary literature.3 In an era of 
Figure 3. Meta-analyses evaluating risk of access site bleeding complications of an ultrasound-guided vs fluoroscopy-guided 
transcatheter aortic valve replacement access strategy. 
Life-threatening, major and minor access site bleeding complications (A), life-threatening and major access site bleeding complications (B), and 
minor access site bleeding complications (C). *Since the study by Potluri et al19 did not report sufficient data to ascertain access site-related 
bleeding complications, bleeding outcomes were taken from Basra et al20; a study from the same center and authors with a overlapping study 
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increasing operator experience in detecting and managing 
vascular complications,29 access site bleeding complica-
tions would less frequently reach the clinical detectability 
or severity threshold that allows their ascertainment as 
Valve Academic Research Consortium-2 end points.
Implications for Clinical Practice
The results of our meta-analysis support the routine 
adoption of ultrasound to guide primary access in TAVR 
as a tool that can modify the risk of vascular and bleed-
ing complications. This is particularly important in the 
TAVR setting, as patients are elderly and comorbid and 
at higher risk of sustaining access site related bleed-
ing complications, than the younger patient groups that 
undergo femoral access for coronary angiography/per-
cutaneous coronary intervention indications. Reducing 
access site complications should lead to reductions in 
the associated morbidity and mortality,1,3 and stream-
line discharge pathways reducing postoperative length 
of stay.30 As TAVR expands to lower risk and younger 
patients with severe aortic stenosis, further reducing 
access site complications with simple, resource neutral 
modifications can improve the risk-benefit and cost-
effectiveness profile of TAVR.
A study by Witberg et al21 suggested that in the 
hands of experienced femoral operators in tertiary cen-
ters with low vascular and bleeding complication rates 
(<7%, respectively) an FCA strategy could match an 
ultrasound-guided strategy. While recognizing the validity 
of this comparison by expert operators in expert centers, 
it is possible to assert that using ultrasound is likely to 
be a more readily trainable and exportable technique. 
This is an important consideration as the volume of TAVR 
increases and as new implantation centers are consid-
ered. Finally, our results are applicable to other proce-
dures requiring percutaneous large-bore access (eg, 
endovascular aneurysm repair, ventricular assist device-
supported percutaneous coronary intervention).
Limitations
First, our study is an aggregate level meta-analysis 
based on low-moderate quality observational studies, 
Figure 4. Meta-analyses evaluating maximally adjusted risk of access site vascular complications of an ultrasound-guided vs 
fluoroscopy-guided transcatheter aortic valve replacement access strategy.
Major and minor access site vascular complications (A), major access site vascular complications (B), and minor access site vascular 
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subject to residual confounding from unadjusted fac-
tors such as peripheral arterial disease, radial second-
ary access, vascular closure device type and number, and 
sheath to femoral artery ratio. To explore the influence of 
confounding, we performed sensitivity analyses includ-
ing studies of maximally adjusted vascular complications 
(propensity-matched or multivariate adjusted outcomes) 
which showed that the direction of the effect estimate 
did not change. Second, our study includes one study 
that has been presented as an abstract though its inclu-
sion highlights our attempt to minimize the effects of 
publication bias. Third, the studies included in this meta-
analysis lacked the granularity to ascertain the primary 
end points as primary or secondary access related. They 
also do not provide sufficient information to explore vas-
cular closure device failure.
In addition, the time frame of study conduct was 
heterogeneous including patients recruited from 2012 
onwards. This introduces temporal bias related to learn-
ing curves and advances in TAVR technology and patient 
care over time. Unfortunately, we were not able to test 
for temporal trends as the available data lack this level 
of granularity. Nonetheless, 2 studies test the temporal 
effect and found no association with the risk of adverse 
outcomes17,21 while other studies adjust for factors (eg, 
sheath size) associated with procedural advances.7,19 
Finally, there is evidence of substantial heterogeneity in 
some of our meta-analyses. Our heterogeneity sensitivity 
analysis shows that the direction of the primary end points 
effect estimates did not change when heterogeneity (I2) 
was reduced to <50% or studies at serious risk of bias 
were excluded. Nonetheless, many factors can explain 
the between study heterogeneity that is observed. From 
a patient perspective, the reported prevalence of periph-
eral arterial disease varies from 6% to 47.2%.14,17 We 
also note a considerable between study heterogeneity of 
the delivery profile of the implanted systems. One study 
included first generation systems,6 while others included 
Acurate Neo and Lotus tissue heart valves that require 
larger delivery sheaths.17,21 Equally, the complication 
rates of the study by Witberg et al21 are comparatively 
low contributing significantly to the observed heteroge-
neity in total and major access site vascular and bleeding 
complications. Despite these limitations, this is the first 
synthesis of available literature in the field, presenting 
clinically significant findings that remain to be confirmed 
in a randomized study.
Conclusions
Our aggregate level meta-analysis of low-moderate qual-
ity observational studies presents a clinically important 
synthesis of evidence for contemporary TAVR practice. 
The reported significant association of an ultrasound-
guided access approach with reductions in total vascu-
lar and bleeding access site complications by 50% and 
≈40%, respectively, has important patient-oriented rami-
fications for all vascular procedures requiring large-bore 
percutaneous access. We propose a randomized trial 
comparing ultrasound to fluoroscopy-guided percutane-
ous transfemoral access in TAVR to provide high level 
evidence. In the interim considering the resource neutral 
nature of ultrasound guidance and the reducing familiar-
ity of operators with fluoroscopy-guided femoral access, 
ultrasound guidance should be considered to obtain per-
cutaneous access in TAVR.
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